Crucial biological functions of CCL7 in cancer
PeerJ, ISSN: 2167-8359, Vol: 2018, Issue: 6, Page: e4928
2018
- 89Citations
- 93Captures
- 3Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations89
- Citation Indexes89
- 89
- CrossRef65
- Captures93
- Readers93
- 93
- Mentions3
- References2
- 2
- News Mentions1
- 1
Most Recent News
Deciphering Natural Killer Cell Cytotoxicity Against Medulloblastoma in vitro and in vivo: Implications for Immunotherapy
Introduction Medulloblastoma (MB) accounts for 10–20% of paediatric brain tumours, is The WHO prevalent brain tumour in children.1 The disease is classified into four histological
Article Description
Chemokine (C-C motif) ligand 7 (CCL7), a CC chemokine, is a chemotactic factor and attractant for various kinds of leukocytes, including monocytes and neutrophils. CCL7 is widely expressed in multiple cell types and can participate in antiinflammatory responses through binding to its receptors to mediate the recruitment of immune cells. Abnormal CCL7 expression is associated with certain immune diseases. Furthermore, CCL7 plays a pivotal role in tumorigenesis. CCL7 promotes tumor progression by supporting the formation of the tumor microenvironment and facilitating tumor invasion and metastasis, although some studies have suggested that CCL7 has tumor suppressor effects. In this review, we summarize the currently available information regarding the influence of CCL7 on tumors.
Bibliographic Details
10.7717/peerj.4928; 10.7717/peerj.4928/fig-2; 10.7717/peerj.4928/fig-3; 10.7717/peerj.4928/fig-1; 10.7717/peerj.4928/table-1
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85048531318&origin=inward; http://dx.doi.org/10.7717/peerj.4928; http://www.ncbi.nlm.nih.gov/pubmed/29915688; https://peerj.com/articles/4928/fig-2; http://dx.doi.org/10.7717/peerj.4928/fig-2; https://peerj.com/articles/4928/fig-3; http://dx.doi.org/10.7717/peerj.4928/fig-3; https://peerj.com/articles/4928; https://peerj.com/articles/4928/fig-1; http://dx.doi.org/10.7717/peerj.4928/fig-1; https://peerj.com/articles/4928/table-1; http://dx.doi.org/10.7717/peerj.4928/table-1; https://peerj.com/articles/4928/; https://peerj.com/articles/4928.pdf; https://peerj.com/articles/4928.html
PeerJ
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know